Suppr超能文献

SARS-CoV-2 感染后中和抗体和 T 细胞应答的持久性。

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection.

机构信息

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Shanghai Public Health Clinical Center, Shanghai, 201508, China.

出版信息

Front Med. 2020 Dec;14(6):746-751. doi: 10.1007/s11684-020-0822-5. Epub 2020 Oct 5.

Abstract

The ongoing pandemic of Coronavirus disease 19 (COVID-19) is caused by a newly discovered β Coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How long the adaptive immunity triggered by SARS-CoV-2 can last is of critical clinical relevance in assessing the probability of second infection and efficacy of vaccination. Here we examined, using ELISA, the IgG antibodies in serum specimens collected from 17 COVID-19 patients at 6-7 months after diagnosis and the results were compared to those from cases investigated 2 weeks to 2 months post-infection. All samples were positive for IgGs against the S- and N-proteins of SARS-CoV-2. Notably, 14 samples available at 6-7 months post-infection all showed significant neutralizing activities in a pseudovirus assay, with no difference in blocking the cell-entry of the 614D and 614G variants of SARS-CoV-2. Furthermore, in 10 blood samples from cases at 6-7 months post-infection used for memory T-cell tests, we found that interferon γ-producing CD4 and CD8 cells were increased upon SARS-CoV-2 antigen stimulation. Together, these results indicate that durable anti-SARS-CoV-2 immunity is common in convalescent population, and vaccines developed from 614D variant may offer protection from the currently predominant 614D variant of SARS-CoV-2.

摘要

持续的 19 冠状病毒病(COVID-19)大流行是由一种新发现的β冠状病毒引起的,称为严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)。SARS-CoV-2 引发的适应性免疫能持续多久,对于评估二次感染的概率和疫苗的效果具有重要的临床意义。在这里,我们使用 ELISA 法检测了 17 例 COVID-19 患者在确诊后 6-7 个月采集的血清标本中的 IgG 抗体,并将结果与感染后 2 周到 2 个月时的病例进行了比较。所有样本均对 SARS-CoV-2 的 S 和 N 蛋白产生 IgG 抗体呈阳性。值得注意的是,在感染后 6-7 个月时,14 个样本在假病毒测定中均显示出显著的中和活性,对 SARS-CoV-2 的 614D 和 614G 变异体的细胞进入阻断无差异。此外,在 10 份感染后 6-7 个月的病例血液样本中,用于记忆 T 细胞测试,我们发现 SARS-CoV-2 抗原刺激后,产生干扰素 γ 的 CD4 和 CD8 细胞增加。综上所述,这些结果表明,在恢复期人群中普遍存在持久的抗 SARS-CoV-2 免疫,并且由 614D 变异体开发的疫苗可能提供针对目前主要的 SARS-CoV-2 614D 变异体的保护。

相似文献

引用本文的文献

本文引用的文献

1
A Thermostable mRNA Vaccine against COVID-19.一种针对 COVID-19 的耐热 mRNA 疫苗。
Cell. 2020 Sep 3;182(5):1271-1283.e16. doi: 10.1016/j.cell.2020.07.024. Epub 2020 Jul 23.
5
8
Viral and host factors related to the clinical outcome of COVID-19.与 COVID-19 临床结果相关的病毒和宿主因素。
Nature. 2020 Jul;583(7816):437-440. doi: 10.1038/s41586-020-2355-0. Epub 2020 May 20.
10
Coronavirus disease 2019 (COVID-19): a clinical update.新型冠状病毒病 2019(COVID-19):临床更新。
Front Med. 2020 Apr;14(2):126-135. doi: 10.1007/s11684-020-0767-8. Epub 2020 Apr 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验